Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials
Abstract Objective In the present study, we aimed to compare the clinical efficacy and safety of omadacycline (OMC) with its comparators for the treatment of complicated skin and soft tissue infections (cSSTIs) in adult patients. Methods Randomized controlled trials (RCTs) evaluating OMC for cSSTIs...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-02-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-024-09097-3 |
| _version_ | 1797275694729789440 |
|---|---|
| author | Wenxin Liang Hong Yin Huiling Chen Juan Xu Yun Cai |
| author_facet | Wenxin Liang Hong Yin Huiling Chen Juan Xu Yun Cai |
| author_sort | Wenxin Liang |
| collection | DOAJ |
| description | Abstract Objective In the present study, we aimed to compare the clinical efficacy and safety of omadacycline (OMC) with its comparators for the treatment of complicated skin and soft tissue infections (cSSTIs) in adult patients. Methods Randomized controlled trials (RCTs) evaluating OMC for cSSTIs were searched in databases of PubMed, Embase, Cochrane, Web of Science, and Clinical Trial, up to July 2022. The primary outcomes were clinical efficacy and microbiological response, with secondary outcome was safety. Results Four RCTs consisting of 1,757 patients were included, with linezolid (LZD) as a comparator drug. For clinical efficacy, OMC was not inferior to LZD in the modified intent-to-treat (MITT) (OR: 1.24, 95% Cl: [0.93, 1.66], P = 0.15) and clinically evaluable (CE) populations (OR: 1.92, 95% Cl: [0.94, 3.92], P = 0.07). For microbiological response, OMC was numerically higher than LZD in the microbiologically evaluable (ME) (OR: 1.74, 95% Cl: [0.81, 3.74], P = 0.16) and microbiological MITT (micro-MITT) populations (OR: 1.27, 95% Cl: [0.92, 1.76], P = 0.14). No significant difference was found in subpopulations of monomicrobial or polymicrobial mixed infection populations. The mortality and adverse event rates were similar between OMC and LZD. Conclusions OMC was as good as LZD in terms of clinical efficacy and microbiological response, and has similar safety issues in treating cSSTIs. OMC might be a promising option for treating cSSTIs in adult patients. |
| first_indexed | 2024-03-07T15:18:12Z |
| format | Article |
| id | doaj.art-92c50de3a33b4640856c14023147364b |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-03-07T15:18:12Z |
| publishDate | 2024-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-92c50de3a33b4640856c14023147364b2024-03-05T17:48:35ZengBMCBMC Infectious Diseases1471-23342024-02-0124111310.1186/s12879-024-09097-3Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trialsWenxin Liang0Hong Yin1Huiling Chen2Juan Xu3Yun Cai4Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, Chinese PLA General HospitalDepartment of Pharmacy, Medical Supplies Center, Chinese PLA General HospitalCenter of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, Chinese PLA General HospitalCenter of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, Chinese PLA General HospitalCenter of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, Chinese PLA General HospitalAbstract Objective In the present study, we aimed to compare the clinical efficacy and safety of omadacycline (OMC) with its comparators for the treatment of complicated skin and soft tissue infections (cSSTIs) in adult patients. Methods Randomized controlled trials (RCTs) evaluating OMC for cSSTIs were searched in databases of PubMed, Embase, Cochrane, Web of Science, and Clinical Trial, up to July 2022. The primary outcomes were clinical efficacy and microbiological response, with secondary outcome was safety. Results Four RCTs consisting of 1,757 patients were included, with linezolid (LZD) as a comparator drug. For clinical efficacy, OMC was not inferior to LZD in the modified intent-to-treat (MITT) (OR: 1.24, 95% Cl: [0.93, 1.66], P = 0.15) and clinically evaluable (CE) populations (OR: 1.92, 95% Cl: [0.94, 3.92], P = 0.07). For microbiological response, OMC was numerically higher than LZD in the microbiologically evaluable (ME) (OR: 1.74, 95% Cl: [0.81, 3.74], P = 0.16) and microbiological MITT (micro-MITT) populations (OR: 1.27, 95% Cl: [0.92, 1.76], P = 0.14). No significant difference was found in subpopulations of monomicrobial or polymicrobial mixed infection populations. The mortality and adverse event rates were similar between OMC and LZD. Conclusions OMC was as good as LZD in terms of clinical efficacy and microbiological response, and has similar safety issues in treating cSSTIs. OMC might be a promising option for treating cSSTIs in adult patients.https://doi.org/10.1186/s12879-024-09097-3OmadacyclineLinezolidComplicated skin and soft tissue infectionsAminomethylcycline |
| spellingShingle | Wenxin Liang Hong Yin Huiling Chen Juan Xu Yun Cai Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials BMC Infectious Diseases Omadacycline Linezolid Complicated skin and soft tissue infections Aminomethylcycline |
| title | Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials |
| title_full | Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials |
| title_fullStr | Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials |
| title_full_unstemmed | Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials |
| title_short | Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials |
| title_sort | efficacy and safety of omadacycline for treating complicated skin and soft tissue infections a meta analysis of randomized controlled trials |
| topic | Omadacycline Linezolid Complicated skin and soft tissue infections Aminomethylcycline |
| url | https://doi.org/10.1186/s12879-024-09097-3 |
| work_keys_str_mv | AT wenxinliang efficacyandsafetyofomadacyclinefortreatingcomplicatedskinandsofttissueinfectionsametaanalysisofrandomizedcontrolledtrials AT hongyin efficacyandsafetyofomadacyclinefortreatingcomplicatedskinandsofttissueinfectionsametaanalysisofrandomizedcontrolledtrials AT huilingchen efficacyandsafetyofomadacyclinefortreatingcomplicatedskinandsofttissueinfectionsametaanalysisofrandomizedcontrolledtrials AT juanxu efficacyandsafetyofomadacyclinefortreatingcomplicatedskinandsofttissueinfectionsametaanalysisofrandomizedcontrolledtrials AT yuncai efficacyandsafetyofomadacyclinefortreatingcomplicatedskinandsofttissueinfectionsametaanalysisofrandomizedcontrolledtrials |